Table 3 Demographic, clinical, and pathological features and ICR expressions on tumor-infiltrating CD8+ T cells
PD-1+CD8+ T cells | CTLA-4+CD8+ T cells | TIGIT+ CD8+ T cells | LAG-3+ CD8+ T cells | TIM-3+ CD8+ T cells | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Median (min–max) | p | Median (min–max) | p | Median (min–max) | p | Median (min-max) | p | Median (min–max) | p | |
Age | ||||||||||
≤ 50(n: 18) | 2.1 (0.3–49) | 0.97 | 5.5 (0.2–52) | 0.64 | 1.3 (0.6–11) | 0.08 | 2.4 (0.5–64) | 0.28 | 3.4 (0.2–63) | 0.89 |
> 50 (n:14) | 10.5 (1.3–42) | 7.5 (0–18) | 6.6 (0.2–50) | 7.5 (0.2–40) | 7.4 (0.3–30) | |||||
Menopausal status | ||||||||||
Pre (n:17) | 2 (0.3–49) | 0.86 | 6 (0.2–52) | 0.40 | 1.3 (0.6–11) | 0.04 | 2.8 (0.6–64) | 0.88 | 4 (0.2–63) | 0.69 |
Post(n:15) | 3.8 (0–9) | 6 (0–16) | 6.9 (0.2–50) | 5.5 (0.2–40) | 6 (0.3–30) | |||||
HER-2 | ||||||||||
Negative (n:21) | 2.7 (0–16) | 0.76 | 6 (0–19) | 0.53 | 1.5 (0,6–43) | 0.37 | 3.8 (0.2–40) | 0.63 | 4 (0.3–27) | 0.18 |
Positive (n:11) | 3 (0.3–49) | 6 (0.3–52) | 6 (0.2–50) | 4 (0.6–64) | 11 (0.2–63) | |||||
Ki-67 | ||||||||||
≤ 20 (n:5) | 0.5 (0–49) | 0.55 | 4 (0–52) | 0.62 | 6.9 (0.2–25) | 0.60 | 10.4 (1.2–64) | 0.26 | 1.2 (1–63) | 0.77 |
> 20 (n:27) | 3 (0.3–16) | 6 (0.2–19) | 2 (0.6–50) | 3.8 (0.2–27) | 5 (0.2–30) | |||||
Histologic grade | ||||||||||
Grade 2 (n:10) | 2.5 (0–49) | 0.72 | 7.5 (0–52) | 0.26 | 4.1 (0.9–43) | 0.39 | 9.7 (0.8–64) | 0.07 | 6.8 (1–63) | 0.62 |
Grade 3 (n:22) | 3 (0.3–16) | 4.6 (0.2–18) | 2 (0.2–50) | 2.5 (0.2–27) | 3.9 (0.2–30) | |||||
High TIL density (>%10) | ||||||||||
Negative (n:20) | 2.9 (0–49) | 0.81 | 8 (0–52) | 0.43 | 2.2 (0.2–43) | 0.42 | 5 (1–64) | 0.02 | 4.5 (0.4–63) | 0.92 |
Positive (n:12) | 2.6 (0.4–8) | 4.1 (0.6–15) | 3.7 (0.9–50) | 2 (02–11) | 5.5 (0.2–30) | |||||
Luminal | ||||||||||
Negative (n:6) | 7 (1–49) | 0.07 | 9 (2.7–52) | 0.19 | 6.5 (1.3–30) | 0.12 | 3.4 (0.5–64) | 0.71 | 17.6 (1–63) | 0.06 |
Positive (n:26) | 2.4 (0–16) | 5.5 (0–19) | 1.4 (0.2–50) | 4 (0.2–40) | 4.4 (0.2–27) | |||||
T stage | ||||||||||
T1 (n:9) | 0.9 (0.3–6.1) | 0.02 | 4 (0.2–18) | 0.41 | 1.1 (0.2–17) | 0.09 | 1.7 (0.2–27) | 0.09 | 1.2 (0.2–19) | 0.33 |
T2 (n:23) | 3.8 (0–49) | 7 (0–52) | 4 (0.6–50) | 4 (0.5–64) | 5 (0.4–63) | |||||
N stage | ||||||||||
N0 (n:23) | 2 (0–49) | 0.41 | 6 (0–52) | 0.78 | 2.4 (0.2–50) | 0.80 | 3.8 (0.2–64) | 0.98 | 6 (0.2–63) | 0.73 |
N1 (n:9) | 3 (0.5–9) | 6 (1.1–16) | 1.5 (0.6–35) | 4 (0.8–24) | 4.9 (1.5–12) | |||||
Lympho-vascular invasion | ||||||||||
Negative (n:16) | 2.5 (0–8) | 0.33 | 3 (0–19) | 0.11 | 1.8 (0.2–43) | 0.70 | 2.9 (0.2–40) | 0.20 | 3.4 (0.2–30) | 0.16 |
Positive (n:16) | 3.4 (0.3–49) | 10 (0.2–52) | 2.2 (0.6–50) | 4.2 (1–64) | 7.5 (0.7–63) | |||||
Extensive intraductal component | ||||||||||
Negative (n:21) | 2.2 (0–8) | 0.2 | 6 (0–19) | 0.45 | 1.3 (0.2–43) | 0.23 | 3.8 (0.8–40) | 0.84 | 4 (0.4–19) | 0.21 |
Positive (n:11) | 3.8 (0.4–49) | 11 (0.6–52) | 5 (0.6–50) | 5.5 (0.2–64) | 9 (0.2–63) | |||||